Effects of Allopurinol on the Progression of Chronic Kidney Disease

• Published in: The New England journal of medicine Vol. 382; no. 26; pp. 2504 - 2513
• Main Authors: Badve, Sunil V, Pascoe, Elaine M, Tiku, Anushree, Boudville, Neil, Brown, Fiona G, Cass, Alan, Clarke, Philip, Dalbeth, Nicola, Day, Richard O, de Zoysa, Janak R, Douglas, Bettina, Faull, Randall, Harris, David C, Hawley, Carmel M, Jones, Graham R.D, Kanellis, John, Palmer, Suetonia C, Perkovic, Vlado, Rangan, Gopala K, Reidlinger, Donna, Robison, Laura, Walker, Robert J, Walters, Giles, Johnson, David W
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 25.06.2020
• Subjects: Aged; Albumin; Allopurinol; Allopurinol - adverse effects; Allopurinol - therapeutic use; Clinical trials; Confidence intervals; Creatinine; Design; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - physiopathology; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - physiopathology; Disease Progression; Double-Blind Method; Drug dosages; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - therapeutic use; Epidemiology; Epidermal growth factor receptors; Female; Glomerular filtration rate; Glomerular Filtration Rate - drug effects; Gout; Gout Suppressants - adverse effects; Gout Suppressants - therapeutic use; Humans; Kidney diseases; Male; Medical research; Middle Aged; Patients; Renal Insufficiency, Chronic - drug therapy; Renal Insufficiency, Chronic - physiopathology; Renin-Angiotensin System; Treatment Failure; Uric acid; Uric Acid - blood; Xanthine Oxidase - antagonists & inhibitors; New Zealand; Australia

This randomized trial assessed whether urate-lowering treatment with allopurinol could attenuate eGFR decline in at-risk patients with stage 3 or 4 chronic kidney disease. Allopurinol did not slow the decline in eGFR as compared with placebo.